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Obese subjects commonly suffer from exertional dyspnea and exercise intolerance. Prelimi-
nary evidence suggests that treatment with nocturnal continuous positive airway pressure
(nCPAP) may improve dyspnea in obese patients with obstructive sleep apnea (OSA), but the
effect on exercise tolerance is unknown. This study sought to investigate whether nCPAP
improves exercise tolerance and exertional dyspnea in obese patients with OSA.
Obese patients prescribed nCPAP for moderate/severe OSA and without cardiopulmonary
disease were recruited. Patients completed a constant-load exercise test and Baseline and
Transitional Dyspnea Index questionnaires (BDI/TDI) at baseline and after one and three
months of nCPAP. Primary outcome was change in constant-load exercise time from baseline
to one and three months. Secondary outcomes included changes in isotime dyspnea, isotime
leg fatigue and BDI/TDI score at one and three months.
Fifteen subjects (body mass index Z 43 kg m-2, apnea-hypopnea index Z 49.hr1) were
studied. Constant-load exercise time increased by 2.0 min (40%, pZ 0.02) at one month and
1.8 min (36%, pZ 0.04) at three months. At one and three months, isotime dyspnea decreased
by 1.4 (pZ 0.17) and 2 units (pZ 0.04), and leg fatigue decreased by 1.2 (pZ 0.18) and 2 units
(pZ 0.02), respectively. BDI/TDI scores were 2.7 (pZ 0.001) and 4.5 points (p < 0.001) at one
and three months. Peak oxygen consumption and static pulmonary function were unchanged.
Nocturnal CPAP improves exercise tolerance and dyspnea in obese patients with OSA. Effects
on exercise time and chronic dyspnea were seen after one and three months of nCPAP, while
exertional dyspnea was only improved at three months.
ª 2011 Elsevier Ltd. All rights reserved.ndex; ANOVA, analysis of variance; BDI/TDI, baseline dyspnea index/transitional dyspnea index; BMI,
city; MRC, Medical Research Council; nCPAP, nocturnal continuous positive airway pressure; OSA,
deviation; VO2, oxygen consumption.
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Exclusion criteria were: known or suspected airways orObesity is associated with multiple medical conditions,
including metabolic, cardiopulmonary and musculoskeletal
diseases,1 and has been identified as an independent risk
factor for premature death.2 Obesity is an established risk
factor for obstructive sleep apnea (OSA)3 and has a number
of profound effects on the cardiac and respiratory systems.
It is well documented that obesity reduces static chest wall
compliance and increases airway resistance due to respi-
ration at lung volumes closer to residual volume.4,5 These
mechanical problems are worsened in the supine position.6
Additionally, the hypercapnic ventilatory response is
reduced in obese subjects compared to non-obese
subjects.7 Obesity also independently affects cardiovas-
cular function by elevating pulmonary artery pressure and
impairing left ventricular diastolic function.8,9 These
cardiopulmonary changes may have important implications
for exercise intolerance in obese individuals.
Obesity is commonly associated with both a decreased
exercise capacity10 and an increase in oxygen cost of
breathing during exercise.11 Exertional dyspnea is also
increased in obese subjects12 and is a prime determinant of
functional impairment.13 The inability to sustain exercise
due to dyspnea results in worsening obesity, decondition-
ing, and an increased risk of cardiovascular disease.14,15
The effects of OSA on exercise are variable. Although
reductions in aerobic capacity have not been consistently
demonstrated,16e20 patients with OSA may have impaired
cardiac stroke volume, inefficient ventilation during exer-
cise and muscle metabolic impairment due to nocturnal
hypoxemia.21e23 Chronic nocturnal continuous positive
airway pressure (nCPAP) has been shown to improve exer-
cise capacity in small studies,24,25 but the effect on dysp-
nea is unknown.
Clinical observation by our group suggests that obese
patients with exertional dyspnea as a presenting symptom
of OSA report an improvement in dyspnea after treatment
with nCPAP, without a change in body mass index (BMI) or
activity level. This reduction in dyspnea may translate into
improved exercise tolerance; however, to date no study has
addressed this interesting question. The aim of the current
study was to test the hypothesis that nCPAP would reduce
exertional dyspnea and improve exercise tolerance in obese
patients with OSA.
Methods
Additional detail on the methods is provided in an online
data supplement.
Patients
Subjects were recruited from referrals to the Foothills
Medical Centre Sleep Centre in Calgary, Alberta, Canada.
Inclusion criteria were: age 18e65 years; BMI  30 kg m2;
a new diagnosis of moderate to severe OSA (Apnea-Hypo-
pnea Index (AHI)  15 h1); decision by the patient and
sleep physician to use nCPAP for treatment of OSA; and
Medical Research Council (MRC) class III or greater dyspnea.parenchymal lung disease; cardiac disease including
pulmonary hypertension; active smoking within the last 6
months; previous treatment for OSA; inability to tolerate
nCPAP; another sleep disorder; inability to perform cycle
ergometry; or refusal or inability to provide informed
consent. All subjects signed an informed consent that had
received approval from the University of Calgary Conjoint
Health Research Ethics Board.
Study design
This pilot study used a prospective, single group design. At
baseline, subjects completed the dyspnea and physical
activity questionnaires before performing a symptom-
limited incremental exercise test. On a separate day,
patients underwent constant-load exercise testing. The
subjects were then started on nCPAP at a pressure deter-
mined by polysomnography. After one and three months of
nCPAP, patients repeated both incremental and constant-
load testing on separate days and completed the dyspnea
and physical activity questionnaires. Pulmonary function
measurements were repeated after three months. Investi-
gators were blind to the results of all measurements until
the conclusion of the study.
Specific methodology
Incremental cardiopulmonary exercise test
Incremental cardiopulmonary exercise testing to symptom
limitation was performed according to American Thoracic
Society guidelines.26
Constant-load exercise trials
A symptom-limited constant-load exercise trial was per-
formed at 85% of maximal workload achieved in the base-
line incremental exercise trial. Exertional symptoms using
the modified Borg scale,27 and repetitive inspiratory
capacity (IC) maneuvers were performed every 2 min.
Measurements of dyspnea and physical activity
The Baseline Dyspnea Index/Transitional Dyspnea Index
questionnaire (BDI/TDI) was used to assess changes in
chronic dyspnea. The BDI is a baseline measure of chronic
dyspnea, while the TDI quantifies the change from baseline.
The Godin Leisure Time Exercise questionnaire was also
used to account for activity as a possible contributor to
increased exercise tolerance.28
Outcomes
The primary outcome was the change in constant-load
exercise time from baseline to one and three months after
the initiation of nCPAP. Secondary outcomes included the
changes in isotime exertional symptoms and chronic exer-
tional dyspnea from baseline to one and three months.
Isotime was defined as the exercise time at symptom limi-
tation during the shortest of the three constant-load trials.
Statistical analysis
One-way repeated measures analysis of variance (ANOVA)
was used to compare primary and secondary outcomes at
CPAP improves exercise tolerance in OSA 1567baseline, one month and three months. Post-hoc compari-
sons were performed using Tukey’s method. Linear regres-
sion was used to determine predictors of the primary and
secondary outcomes. To examine the possible mechanisms
for improved exercise tolerance, the relationships between
mean Borg scores, oxygen consumption (VO2) and ventila-
tion were plotted for the baseline and three month incre-
mental cardiopulmonary exercise tests, as previously
described.29 Comparison of these plots was performed
using two-way repeated measures ANOVA. All statistics
were performed using Intercooled Stata version 11 (Stata-
Corp, College Station, TX). Values are represented as
mean  standard deviation (SD).
Results
The study patient flow is presented in Fig. 1. Recruitment
took place between August 2007 and April 2009. Out of 87
patients who were screened, 27/87 (31%) were deemed
eligible and consented to participate, and 23/27 (85%)
started nCPAP. Fifteen subjects completed the study and
were included in the primary analysis. There were no
adverse events due to nCPAP or any of the study
procedures.
Patient characteristics
Table 1 shows the baseline clinical characteristics for the
study population. Fifteen subjects (six males, nine females)
participated in the study. Mean age was 49  6 years, with
a mean BMI of 42.6  8.8 kg m-2. Mean BDI score was
6.9  0.7. Mean peak VO2 was 17.0  4.2 mL/kg/min.Figure 1 StudyThe effect of nocturnal CPAP on exercise tolerance
and exertional symptoms
Table 2 shows baseline and follow-up physiologic data.
Compared to baseline (5.1  2.0 min), exercise time
increased by 2.0 min (7.1  4.7 min, p Z 0.02) after one
month of nCPAP and by 1.8 min (6.9  3.8 min, p Z 0.04)
after three months of nCPAP (Fig. 2). There was no differ-
ence between the one month and three-month constant-
load times. During this time, there was no change in BMI,
leisure-time exercise, spirometry, diffusion capacity for
carbon monoxide, blood pressure, peak VO2, peak IC or
oxyhemoglobin saturation. Average nCPAP usage was
5.8  2 h, with a residual AHI of 4.7  2.5 h-1.
From baseline to one and three months, respectively,
the isotime Borg dyspnea score decreased by 1.4 and 2.0
points (from 7.3  2.4 to 5.9  2.4 at one month (pZ 0.17)
and 5.3  2.9 at three months (p Z 0.04)), and the leg
discomfort score decreased by 1.2 and 2.0 points (from
8.1  2.3 to 6.9  2.9 at one month (p Z 0.18) and
6.1  2.6 at three months (p Z 0.02)). There was no
significant change in isotime dyspnea or leg discomfort from
one to three months. The Borg scores at symptom limitation
did not change from baseline to one and three months,
although they were reached after a longer duration of
exercise (Fig. 3). There was no change in isotime minute
ventilation, oxygen pulse or inspiratory capacity between
baseline and three month testing. There was an association
between constant-load exercise time and isotime dyspnea
between baseline and one month (R2 Z 0.43, p Z 0.008),
which was also seen at three months (R2 Z 0.45,
p Z 0.006). There was no association between the change
in exercise time or exertional symptoms and AHI, nocturnalpatient flow.
Table 1 Patient characteristics.
Characteristic Value
Age (y) 49  6
Subjects (M,F) 15 (6,9)
Body mass index (kg m2) 42.6  8.8
Apnea/hypopnea index (hr1) 48.1  33.1
Mean nocturnal oxygen saturation (%) 92.4  2.1
% of night with SpO2 < 90% 26.0  25.8
nCPAP pressure (cm H2O) 9.7  2.8
MRC score 3.1  1.2
Baseline dyspnea index score 6.9  0.7
Epworth sleepiness score 15  6
Definition of abbreviations: SpO2Z oxyhemoglobin saturation, nCPAPZ nocturnal continuous positive airway pressure, MRCZ Medical
Research Council. Values are mean  SD.
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(ESS) or change in ESS from baseline to three months.
The effect of nocturnal CPAP on chronic dyspnea
At one and three months, the respective TDI overall scores
were 2.7  2.3 (p Z 0.001 for difference from 0) and
4.5  2.9 (p < 0.001). Improvements in dyspnea were seen
in all three components of the TDI. There was a trend
toward a reduction in MRC class (3.0e2.5, p Z 0.054).
There was no difference in metabolic equivalents using the
Godin Leisure Time Exercise questionnaire. The ESS
improved from 15 at baseline to 6 at the three month
follow-up assessment.
Relationships between exertional symptoms,
oxygen consumption and ventilation
Fig. 4 shows the plotted graphs of exertional symptoms at
varying mean levels of VO2 and ventilation. There was
a trend to reduction in mean Borg dyspnea scores at peakTable 2 Physiologic data.
Measurement Baseline 1-M
Value % Predicted Valu
FVC (L) 3.72  0.85 99
FEV1 (L) 2.95  0.72 97
DLCO (mL/mmHg/min) 27.34  6.76 89
Peak VO2 (mL/min) 2108  602 103 2
Peak VO2 (mL/kg/min) 17.0  4.2 60 1
Peak workload (W) 126  36 e
Peak heart rate (bpm) 136  19 79
Peak O2 pulse (L) 15.7  3.8 124 1
Peak blood pressure
(mmHg)
181/98  33/10 e 184
Peak ventilation
(L min-1)
72  24 66
Peak IC (L) 3.05  0.83 e 2
Definition of abbreviations: FVCZ forced vital capacity, FEV1Z forc
for carbon monoxide, VO2 Z oxygen consumption, IC Z inspiratory cVO2 from baseline to three months (p Z 0.068). Mean Borg
leg discomfort was similar at all levels of VO2. At ventilation
above 50 L/min, there was also a trend towards a lower
mean Borg dyspnea score at three months compared to
baseline (p Z 0.078).Discussion
The principal novel finding of this study is that nCPAP
improves constant-load exercise time in obese subjects
with OSA and dyspnea as a presenting complaint. This
effect was seen one and three months after nCPAP initia-
tion. The improvement in exercise time was accompanied
by reductions in isotime measurements of exertional
dyspnea and leg fatigue. Additionally, measures of chronic
dyspnea were also improved with this intervention. These
results occurred without changes in BMI, pulmonary func-
tion, physical activity or fitness. Our findings support the
study hypothesis that nCPAP improves dyspnea and exercise
tolerance in this population of patients.onth follow-up 3-Month follow-up
e % Predicted Value % Predicted
e e 3.73  0.85 98
e e 2.9  0.67 96
e e 27.97  5.88 90
081  507 103 2090  532 105
6.5  3.5 59 16.6  3.5 59.2
118  34 e 124  30 e
137  21 80 136  18 80
5.3  3.5 122 15.3  3.6 123
/94  26/8 e 185/96  32/13 e
73  19 66 73  21 68
.99  0.67 e 3.05  0.83 e
ed expiratory volume in 1 s, DLCOZ diffusion capacity of the lung
apacity. Values are mean  SD.
Figure 2 Exercise time during constant-load exercise at
baseline and after one and three months of nCPAP. Values
represent mean  SD, )p < 0.05.
CPAP improves exercise tolerance in OSA 1569To our knowledge, this is the first study to investigate
whether dyspnea and exercise intolerance experienced by
obese subjects with OSA can be improved with nCPAP; thus,
it is difficult to compare our findings to previous work in this
area. Lin and colleagues demonstrated improvements in
peak VO2, anaerobic threshold, peak workload, oxygen
pulse and ventilation at maximal exercise after two monthsFigure 3 Dyspnea and leg fatigue during constant-load exercise
represent mean SD, )p < 0.05.
Figure 4 Relationship between a) exertional dyspnea and oxyge
exertional dyspnea and ventilation at baseline and after three moof nCPAP therapy in 20 subjects with OSA.25 Alonso-
Fernandez et al. showed a reduced stroke volume
response to exercise in 31 OSA patients compared to 15
control subjects, and demonstrated the reversal of this
phenomenon after 3 months of nCPAP.21 In contrast to the
present investigation, these studies included non-obese
subjects with abnormal right or left ventricular function
at baseline, and did not include patients with dyspnea as
a presenting complaint. Additionally, these authors did not
measure physical activity between cardiopulmonary exer-
cise tests, which could have confounded their results.
There are a number of potential mechanisms for the
increase in constant-load exercise time demonstrated in
this cohort. Nocturnal CPAP may confer mechanical bene-
fits to the respiratory system. At rest and during exercise,
obesity increases the mechanical load on the respiratory
system through a reduction in chest wall compliance and
due to increased intrinsic positive end expiratory pressure
from expiratory flow limitation.4,29,30 Consequently, the
functional residual capacity in obese subjects is reduced.31
The supine position worsens these mechanical limitations in
obese subjects,4,6 which could result in lower lung volumes
and micro-atelectasis during sleep. Acute CPAP has been
shown to reduce atelectasis in obese subjects32 but to our
knowledge there are no studies examining the effect of
nCPAP on respiratory mechanics. Our study showed a trend
toward a decreased Borg dyspnea score for a given venti-
lation, supporting a mechanical cause of improved exer-
tional dyspnea with nCPAP. The reduction in exertionalat baseline and after one and three months of nCPAP. Values
n consumption (VO2), b) exertional leg discomfort and VO2, c)
nths of nCPAP. Values represent mean SE, )p < 0.05.
1570 S.R. Pendharkar et al.dyspnea was associated with an increase in exercise time,
providing a link between the mechanical benefits of nCPAP
and the improvement in exercise tolerance.
The cardiovascular benefits of nCPAP have been
demonstrated using imaging and clinical measurements.
Studies of OSA patients using Doppler echocardiography
have demonstrated depressed myocardial contractile
reserve33 and impaired left and right ventricular perfor-
mance despite a normal ejection fraction.34 In patients
with OSA, as assessed by cardiac magnetic resonance
imaging, nCPAP improved right ventricular end diastolic and
systolic volumes without an appreciable change in left
ventricular size or function.35 nCPAP has also been shown to
reduce arterial stiffness, mean peripheral arterial pressure
and central blood pressure in patients with newly diagnosed
OSA, and a deterioration in these parameters was seen
following nCPAP withdrawal.36 We examined oxygen pulse
during exercise as a surrogate of stroke volume, and mean
arterial pressure during exercise. Neither of these measures
changed with nCPAP, suggesting the absence of a cardio-
vascular benefit of nCPAP. Additionally, there was no
change seen in the Borg leg fatigue-VO2 relationship, sug-
gesting that nCPAP did not improve oxygen delivery in these
patients. As such it appears that the improvements in
exercise tolerance are a result of improved pulmonary
mechanics rather than cardiovascular adaptations.
There are a couple of limitations to the present study that
need to be acknowledged. First, we did not randomize
patients to a separate control group as the primary aim was
to “prove-the-principle” that nCPAP could improve dyspnea
and exercise tolerance in obese patients with OSA before
performing amuchmore complex and expensive randomized
trial. Second, while we demonstrated an increase in exercise
tolerance with nCPAP, our study did not seek to delineate
whether this beneficial effect was due to improvements in
mechanical dysfunction related to obesity, cardiopulmonary
perturbations of OSA, or a combination of both. Further
studies are now needed to clearly identify the mechanism
responsible for the improvements in dyspnea and exercise
tolerance with nCPAP in this population.
In conclusion, the findings of this pilot study demon-
strate that three months of nCPAP can improve exertional
dyspnea and exercise tolerance in obese patients with OSA.
This study has important clinical implications. With greater
exercise tolerance, obese patients would be able to exer-
cise more, promoting weight loss as a management strategy
for OSA. Weight loss and increased physical activity could
also have more general health benefits such as cardiovas-
cular risk reduction. Further studies are now warranted to
definitively address these questions.Conflict of interest statement
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